Drug Trial Radar · NCT06217562
Vasopressin for Septic Shock Pragmatic Trial
Last checked: Nov 19, 2026Latest source record: Aug 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,959
Actual
Start
Feb 1, 2024
Primary completion
Feb 17, 2026
Study completion Jun 6, 2026
Sponsor
- Lead sponsor
- Intermountain Health Care, Inc.Academic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Utah
- First posted
- Jan 22, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Life-threatening low blood pressure due to a serious infection is called "septic shock." Septic shock is treated with vasopressors, medications that raise blood pressure. Sometimes first-line vasopressors are inadequate, prompting addition of a second-line vasopressor called vasopressin. However, the threshold at which to start vasopressin remains unclear. This pragmatic, cluster-randomized, cluster-crossover trial will evaluate two different strategies for septic shock treatment commonly used in current practice, comparing a lower versus a higher threshold for adding vasopressin to first-line vasopressors.
Conditions
- Septic Shock
Interventions
VasopressinDrug
Intravenous vasopressin infusion added to first-line vasopressors. Recommended vasopressin dose is 1.8 units/hour (equivalent to 0.03 units/minute) at a fixed rate.
Recommendation to use a lower initiation threshold for vasopressinOther
Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.1 mcg/kg/min of norepinephrine (or equivalent)
Recommendation to use a higher initiation threshold for vasopressinOther
Recommended to initiate intravenous vasopressin infusion if the combined dose of other vasopressors reaches ≥0.4 mcg/kg/min of norepinephrine (or equivalent)
Primary outcomes
What the sponsor says the trial is designed to measure.
- 28-day all-cause mortalityTime frame: 28 days
Locations
13 sites in 1 country. Site status is shown where the registry gives one.
Cassia Regional Hospital
Burley, Idaho
American Fork Hospital
American Fork, Utah
Cedar City Hospital
Cedar City, Utah
Layton Hospital
Layton, Utah
Logan Regional Hospital
Logan, Utah
Intermountain Medical Center
Murray, Utah
McKay-Dee Hospital
Ogden, Utah
Park City Hospital
Park City, Utah
Utah Valley Hospital
Provo, Utah
Riverton Hospital
Riverton, Utah
LDS Hospital
Salt Lake City, Utah
Alta View Hospital
Sandy City, Utah
St. George Regional Hospital
St. George, Utah
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.